📊 TEVJF Key Takeaways
Is Teva Pharmaceutical Industries Ltd. (TEVJF) a Good Investment?
Severe data quality issues undermine confidence in reported profitability metrics (gross margin 595.9% exceeds 100%, indicating mathematical impossibility). Excluding suspicious margin data, company shows strong balance sheet and FCF generation, but weak fundamentals including 4.3% revenue growth and declining net income present headwinds.
Why Buy Teva Pharmaceutical Industries Ltd. Stock? TEVJF Key Strengths
- Exceptional balance sheet with minimal debt (0.01x D/E ratio) and $3.6B cash
- Strong free cash flow generation ($1.1B annually, 76.5% FCF margin)
- Solid operating cash flow ($1.6B) demonstrates earnings quality
TEVJF Stock Risks: Teva Pharmaceutical Industries Ltd. Investment Risks
- Critical data integrity issues: gross profit exceeds revenue (mathematically impossible)
- Anemic revenue growth (4.3% YoY) with net income declining 0.6% YoY
- Liquidity deterioration: quick ratio 0.80x below 1.0 threshold; current ratio barely adequate at 1.04x
Key Metrics to Watch
- Revenue growth trajectory and pharmaceutical segment performance
- Gross profit and margin reconciliation with audited 10-K filing
- Working capital trends and quick ratio improvement
Teva Pharmaceutical Industries Ltd. (TEVJF) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The 76.5% free cash flow margin provides substantial flexibility for dividends, buybacks, and strategic investments.
TEVJF Profit Margin, ROE & Profitability Analysis
TEVJF vs Healthcare Sector: How Teva Pharmaceutical Industries Ltd. Compares
How Teva Pharmaceutical Industries Ltd. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Teva Pharmaceutical Industries Ltd. Stock Overvalued? TEVJF Valuation Analysis 2026
Based on fundamental analysis, Teva Pharmaceutical Industries Ltd. appears fundamentally strong relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Teva Pharmaceutical Industries Ltd. Balance Sheet: TEVJF Debt, Cash & Liquidity
TEVJF Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Teva Pharmaceutical Industries Ltd.'s revenue has shown modest growth of 2% over the 5-year period. The most recent EPS of $-0.50 indicates the company is currently unprofitable.
TEVJF Revenue Growth, EPS Growth & YoY Performance
TEVJF Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $4.3B | $433.0M | $0.37 |
| Q2 2025 | $4.2B | $282.0M | $0.24 |
| Q1 2025 | $3.8B | -$139.0M | $-0.12 |
| Q3 2024 | $3.9B | $69.0M | $0.06 |
| Q2 2024 | $3.9B | -$846.0M | $-0.75 |
| Q1 2024 | $3.7B | -$139.0M | $-0.12 |
| Q3 2023 | $3.6B | $56.0M | $0.05 |
| Q2 2023 | $3.8B | -$232.0M | $-0.21 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Teva Pharmaceutical Industries Ltd. Dividends, Buybacks & Capital Allocation
TEVJF SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Teva Pharmaceutical Industries Ltd. (CIK: 0000818686)
📋 Recent SEC Filings
❓ Frequently Asked Questions about TEVJF
What is the AI rating for TEVJF?
Teva Pharmaceutical Industries Ltd. (TEVJF) has an AI rating of HOLD with 45% confidence, based on fundamental analysis of SEC EDGAR filings.
What are TEVJF's key strengths?
Claude: Exceptional balance sheet with minimal debt (0.01x D/E ratio) and $3.6B cash. Strong free cash flow generation ($1.1B annually, 76.5% FCF margin).
What are the risks of investing in TEVJF?
Claude: Critical data integrity issues: gross profit exceeds revenue (mathematically impossible). Anemic revenue growth (4.3% YoY) with net income declining 0.6% YoY.
What is TEVJF's revenue and growth?
Teva Pharmaceutical Industries Ltd. reported revenue of $1.5B.
Does TEVJF pay dividends?
Teva Pharmaceutical Industries Ltd. pays dividends, with $12.0M distributed to shareholders in the trailing twelve months.
Where can I find TEVJF SEC filings?
Official SEC filings for Teva Pharmaceutical Industries Ltd. (CIK: 0000818686) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is TEVJF's EPS?
Teva Pharmaceutical Industries Ltd. has a diluted EPS of $1.21.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is TEVJF a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Teva Pharmaceutical Industries Ltd. has a HOLD rating with 45% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is TEVJF stock overvalued or undervalued?
Valuation metrics for TEVJF: ROE of 17.8% (sector avg: 15%), net margin of 94.0% (sector avg: 12%). Higher ROE suggests strong returns relative to peers.
Should I buy TEVJF stock in 2026?
Our dual AI analysis gives Teva Pharmaceutical Industries Ltd. a combined HOLD rating for 2026. Revenue is data pending, with profitability above sector average. Always conduct your own research.
What is TEVJF's free cash flow?
Teva Pharmaceutical Industries Ltd.'s operating cash flow is $1.6B, with capital expenditures of $501.0M. FCF margin is 76.5%.
How does TEVJF compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 94.0% (avg: 12%), ROE 17.8% (avg: 15%), current ratio 1.04 (avg: 2).